Company Focus
CellTrion
Latest CellTrion News
Biosimilars
South Korean biosimilar firm Samsung Bioepis, a wholly owned subsidiary of Samsung Epis Holdings, expects to put a pre-filled syringe version of its Eylea copy Opuviz (aflibercept) on the European market in the third quarter, a few months after launching the vial presentation into a field already thick with rivals. 10 August 2026
Related News
Insights
Company Spotlight
An American biotech company developing gene-modulating therapies, particularly for neuromuscular diseases.
Latest News & Features of interest to CellTrion
Pharmaceutical
The number of new cancer drugs are being launched in the Russian market is steadily declining these days, which is mainly due to the drop of local demand for them and tough business environment in Russia at present. 14 August 2026
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. 14 August 2026
Biotechnology
US clinical-stage biotech Olema Oncology has announced the appointment of Jason O’Byrne, chief financial officer. (CFO). 14 August 2026
Pharmaceutical
The European Medicines Agency (EMA) has validated the marketing authorization application for PF-07307405, the six-valent Lyme disease vaccine candidate from US pharma major Pfizer and French vaccine specialist Valneva, and has begun its assessment. No human Lyme vaccine is approved anywhere at present. 14 August 2026
Biotechnology
USA-based CNS specialist MapLight Therapeutics announced it has secured approximately $150 million in gross proceeds through a private placement financing (PIPE). 13 August 2026
Pharmaceutical
Japanese drugmaker Otsuka’s Taiho subsidiaries and Cullinan Therapeutics today announced that the REZILIENT3 trial, a global Phase III clinical study evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy met its primary endpoint of progression-free survival (PFS) at a planned interim analysis. 13 August 2026
Biotechnology
US biotech Rigel Pharmaceuticals today announced that Veppanu (vepdegestrant), which was authorized for marketing by the Food and Drug Administration in May this year, is now available by prescription in the USA. 13 August 2026
Biotechnology
China’s’ Akeso announced that the China National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for ivonescimab injection in combination with chemotherapy for the first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC). 13 August 2026
Biotechnology
Shares of US late-stage clinical biotech Definium Therapeutics leapt as much as 18% yesterday, after it announced positive top-line results from Voyage, its first Phase III study of DT120 (lysergide) orally disintegrating tablet (ODT) 100 µg in adults with generalized anxiety disorder (GAD). 13 August 2026
Biotechnology
US biotech MacroGenics revealed that Gilead Sciences has exercised its option to secure an exclusive license for a pre-clinical bispecific program, a move that will provide MacroGenics with a $10 million payment. 13 August 2026
Latest In Brief for CellTrion
Pharmaceutical
Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions. 7 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze